REG - CVS Group plc - Exercise of Options and Total Voting Rights

CVSAnnouncement

02/02/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230202:nRSB7938Oa&default-theme=true

RNS Number : 7938O  CVS Group plc  02 February 2023

2 February 2023

CVS Group plc

("CVS" or the "Company")

Exercise of Options and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services,
confirms that certain employees have exercised options during January under
the CVS Group 2019 SAYE Plan (2019/2023) totalling 151,446 ordinary shares of
0.2 pence each ("Ordinary Shares").  Additionally, deferred options over a
total of 1,474 Ordinary Shares were exercised under the CVS Group 2018 SAYE
Plan (2018/2022) taking the total options exercised during January to 152,920
(together, the "SAYE Exercise").

The issuance of shares in connection with the SAYE Exercise was partially
satisfied by 44,491 Ordinary Shares held by the CVS Group Employee Benefit
Trust (the "EBT").  Following the SAYE Exercise, a total of 16,477 Ordinary
Shares are held by the EBT, representing approximately 0.023% of the Company's
total voting rights.

The sum of 108,429 new Ordinary Shares were issued to satisfy the balance of
Ordinary Shares arising from the SAYE Exercise.  Admission of the 108,429 new
Ordinary Shares has been satisfied by the Company's block listing admitted to
the London Stock Exchange on 30 December 2021.

Following the issue of these new Ordinary Shares, which rank pari passu in all
respects with the Company's existing Ordinary Shares, the Company has a total
issued share capital of 71,380,400 Ordinary Shares, each carrying one voting
right. The Company holds no Ordinary Shares in treasury and the total number
of voting rights is therefore 71,380,400.

This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest, or a change to their interest, in the Company under the FCA's
Disclosure Guidance and Transparency Rules.

Contacts:

CVS Group plc
 
                     via Camarco

Richard Fairman, CEO

Jenny Farrer, Company Secretary

 

Peel Hunt LLP (Nominated Adviser & Broker)
                         +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

 

   Berenberg (Joint Broker)
                                                  +44
(0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

 

Camarco (Financial
PR)

Geoffrey Pelham-Lane
                                                 +44
(0)7733 124 226

Ginny Pulbrook
 
     +44 (0)7961 315 138

   Toby Strong
 
             +44 (0)7789 151 644

About CVS Group plc (www.cvsukltd.co.uk (http://www.cvsukltd.co.uk/) )

CVS Group is an AIM-quoted fully-integrated provider of veterinary services
in the UK, with practices in the Netherlands and the Republic of Ireland. CVS
is focused on providing high quality clinical services to its customers and
their animals, with outstanding and dedicated clinical teams and support
colleagues at the core of its strategy.

The Group has c.500 veterinary practices across its three markets, including
eight specialist referral hospitals and 37 dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties), Crematoria
(providing pet cremation and clinical waste disposal for CVS and third-party
practices), Buying Groups and the Group's online retail business ("Animed
Direct").

The Group employs c.8,100 personnel, including c.2,100 veterinary surgeons
and c.3,000 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBLGDDBSGDGXD